Disease · MONDO_0005012
Comparisons in its trials29
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 29
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Combination of Bempegaldesleukin (NKTR-214) + Nivolumab vs Nivolumab: deaths from any cause | 9 of 378 | 4 of 387 | 765 | NCT04410445 | Trial comparisons |
| Combination of Bempegaldesleukin (NKTR-214) + Nivolumab vs Nivolumab: serious adverse events | 74 of 378 | 33 of 387 | 765 | NCT04410445 | Trial comparisons |
| Dabrafenib + Trametinib vs Dabrafenib + Placebo: Objective Response Rate (ORR) as Assessed by the Investigator | 146 of 210 | 113 of 210 | 420 | NCT01584648 | Trial comparisons |
| Cohort 1: 8 HLA-A2-restricted Peptides and CpG 7909 vs Cohort 2: 8 HLA-A2-Restricted Peptides and Montanide ISA51: Number of Patients With Dose Limiting Toxicities (DLT). | 2 of 16 | 0 of 7 | 23 | NCT00145158 | Trial comparisons |
| Cohort 1: 8 HLA-A2-restricted Peptides and CpG 7909 vs Cohort 2: 8 HLA-A2-Restricted Peptides and Montanide ISA51: deaths from any cause | 0 of 16 | 0 of 7 | 23 | NCT00145158 | Trial comparisons |
| Cohort 1: 8 HLA-A2-restricted Peptides and CpG 7909 vs Cohort 2: 8 HLA-A2-Restricted Peptides and Montanide ISA51: serious adverse events | 7 of 16 | 3 of 7 | 23 | NCT00145158 | Trial comparisons |
| PV-10 vs Chemotherapy or Oncolytic Viral Therapy: deaths from any cause | 0 of 14 | 0 of 8 | 22 | NCT02288897 | Trial comparisons |
| PV-10 vs Chemotherapy or Oncolytic Viral Therapy: Number of Participants With Adverse Events | 14 of 14 | 8 of 8 | 22 | NCT02288897 | Trial comparisons |
| PV-10 vs Chemotherapy or Oncolytic Viral Therapy: serious adverse events | 0 of 14 | 1 of 8 | 22 | NCT02288897 | Trial comparisons |
Phase 2, Expansion, Cohort I: Modakafusp Alfa 1.0 mg/kg + Pembrolizumab 400 mg vs Phase 2, Expansion, Cohort II: Modakafusp Alfa 1.0 mg/kg + Pembrolizumab 400 mg: Phase 2 Expansion: Number of Participants With Grade 3 or Higher TEAEs | 6 of 9 | 7 of 12 | 21 | NCT04157517 | Trial comparisons |
Phase 2, Expansion, Cohort I: Modakafusp Alfa 1.0 mg/kg + Pembrolizumab 400 mg vs Phase 2, Expansion, Cohort II: Modakafusp Alfa 1.0 mg/kg + Pembrolizumab 400 mg: Phase 2 Expansion: Number of Participants Reporting One or More TEAEs | 8 of 9 | 12 of 12 | 21 | NCT04157517 | Trial comparisons |
Phase 2, Expansion, Cohort I: Modakafusp Alfa 1.0 mg/kg + Pembrolizumab 400 mg vs Phase 2, Expansion, Cohort II: Modakafusp Alfa 1.0 mg/kg + Pembrolizumab 400 mg: Phase 2 Expansion: Number of Participants Reporting One or More SAEs | 2 of 9 | 6 of 12 | 21 | NCT04157517 | Trial comparisons |
| Intralesional TALIMOGENE LAHERPAREPVEC Without Radiotherapy vs Intralesional TALIMOGENE LAHERPAREPVEC With Radiotherapy: deaths from any cause | 8 of 9 | 9 of 10 | 19 | NCT02819843 | Trial comparisons |
| Intralesional TALIMOGENE LAHERPAREPVEC Without Radiotherapy vs Intralesional TALIMOGENE LAHERPAREPVEC With Radiotherapy: serious adverse events | 0 of 9 | 0 of 10 | 19 | NCT02819843 | Trial comparisons |
| Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1) vs Vaccine + Dasatinib (Cycle 1, D1): deaths from any cause | 8 of 9 | 5 of 6 | 15 | NCT01876212 | Trial comparisons |
| Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1) vs Vaccine + Dasatinib (Cycle 1, D1): serious adverse events | 7 of 9 | 4 of 6 | 15 | NCT01876212 | Trial comparisons |
| PV-10 vs Chemotherapy or Oncolytic Viral Therapy: Complete Response Rate (CRR) | 3 of 9 | 2 of 6 | 15 | NCT02288897 | Trial comparisons |
| Phase I: GSK2118436 150 mg + GSK1120212 2 mg vs Phase II: GSK2118436 150 mg + GSK1120212 2 mg: serious adverse events | 1 of 6 | 0 of 6 | 12 | NCT01928940 | Trial comparisons |
| Nivolumab, NeoVax + Montanide, Ipilimumab (2.5 mg Per Injection Site) vs Nivolumab, NeoVax + Montanide, Ipilimumab (5.0 mg Per Injection Site): deaths from any cause | 1 of 6 | 1 of 5 | 11 | NCT03929029 | Trial comparisons |
| Nivolumab, NeoVax + Montanide, Ipilimumab (2.5 mg Per Injection Site) vs Nivolumab, NeoVax + Montanide, Ipilimumab (5.0 mg Per Injection Site): serious adverse events | 1 of 6 | 1 of 5 | 11 | NCT03929029 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005012/comparisons